89bio Stock Forecast, Price & News

-0.22 (-1.15 %)
(As of 06/21/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume60,748 shs
Average Volume131,036 shs
Market Capitalization$378.33 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ETNB News and Ratings via Email

Sign-up to receive the latest news and ratings for 89bio and its competitors with MarketBeat's FREE daily newsletter.

89bio logo

About 89bio

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.97 out of 5 stars

Medical Sector

100th out of 2,105 stocks

Pharmaceutical Preparations Industry

42nd out of 832 stocks

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

89bio (NASDAQ:ETNB) Frequently Asked Questions

Is 89bio a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" 89bio stock.
View analyst ratings for 89bio
or view top-rated stocks.

What stocks does MarketBeat like better than 89bio?

Wall Street analysts have given 89bio a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but 89bio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is 89bio's next earnings date?

89bio is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for 89bio

How were 89bio's earnings last quarter?

89bio, Inc. (NASDAQ:ETNB) released its earnings results on Tuesday, May, 11th. The company reported ($0.74) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.70) by $0.04.
View 89bio's earnings history

How has 89bio's stock price been impacted by COVID-19?

89bio's stock was trading at $33.55 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ETNB stock has decreased by 43.8% and is now trading at $18.86.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ETNB?

8 brokers have issued 12 month price targets for 89bio's stock. Their forecasts range from $35.00 to $95.00. On average, they anticipate 89bio's stock price to reach $58.13 in the next year. This suggests a possible upside of 208.2% from the stock's current price.
View analysts' price targets for 89bio
or view top-rated stocks among Wall Street analysts.

Who are 89bio's key executives?

89bio's management team includes the following people:
  • Mr. Rohan Palekar, CEO & Director (Age 55, Pay $869.65k)
  • Mr. Quoc Le-Nguyen, Chief Technical Operations Officer & Head of Quality (Age 53, Pay $555.38k)
  • Dr. Harry Mansbach M.D., Chief Medical Officer (Age 56, Pay $650k)
  • Mr. Ryan Stephen Martins, Chief Financial Officer (Age 44)
  • Mr. Ram Waisbourd, COO & Chief Bus. Officer (Age 54)

Who are some of 89bio's key competitors?

What other stocks do shareholders of 89bio own?

When did 89bio IPO?

(ETNB) raised $70 million in an initial public offering (IPO) on the week of November 11th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.

What is 89bio's stock symbol?

89bio trades on the NASDAQ under the ticker symbol "ETNB."

Who are 89bio's major shareholders?

89bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.50%), Acuta Capital Partners LLC (1.96%), Morgan Stanley (1.69%), JPMorgan Chase & Co. (1.08%), Pekin Hardy Strauss Inc. (0.91%) and Geode Capital Management LLC (0.71%). Company insiders that own 89bio stock include Gregory Grunberg, Longitude Capital Partners Iii, Orbimed Advisors Llc, Ra Capital Management, LP, Ram Waisbourd and Ryan Martins.
View institutional ownership trends for 89bio

Which institutional investors are selling 89bio stock?

ETNB stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Acuta Capital Partners LLC, Phoenix Holdings Ltd., Alyeska Investment Group L.P., JPMorgan Chase & Co., Squarepoint Ops LLC, Northern Trust Corp, and Millennium Management LLC. Company insiders that have sold 89bio company stock in the last year include Gregory Grunberg, Orbimed Advisors Llc, Ram Waisbourd, and Ryan Martins.
View insider buying and selling activity for 89bio
or view top insider-selling stocks.

Which institutional investors are buying 89bio stock?

ETNB stock was purchased by a variety of institutional investors in the last quarter, including Pekin Hardy Strauss Inc., Verition Fund Management LLC, BlackRock Inc., Geode Capital Management LLC, Goldman Sachs Group Inc., Cubist Systematic Strategies LLC, Bourgeon Capital Management LLC, and Chicago Partners Investment Group LLC. Company insiders that have bought 89bio stock in the last two years include Longitude Capital Partners Iii, Orbimed Advisors Llc, and Ra Capital Management, LP.
View insider buying and selling activity for 89bio
or or view top insider-buying stocks.

How do I buy shares of 89bio?

Shares of ETNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 89bio's stock price today?

One share of ETNB stock can currently be purchased for approximately $18.86.

How much money does 89bio make?

89bio has a market capitalization of $378.33 million. The company earns $-49,500,000.00 in net income (profit) each year or ($3.08) on an earnings per share basis.

How many employees does 89bio have?

89bio employs 26 workers across the globe.

What is 89bio's official website?

The official website for 89bio is

Where are 89bio's headquarters?

89bio is headquartered at 142 SANSOME STREET SECOND FLOOR, SAN FRANCISCO CA, 94104.

How can I contact 89bio?

89bio's mailing address is 142 SANSOME STREET SECOND FLOOR, SAN FRANCISCO CA, 94104. The company can be reached via phone at 415-500-4614 or via email at [email protected]

This page was last updated on 6/22/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.